Brind.

A price target raise for Hinge Health following the company's Q2 results and guidance, driven by the company's performance.

1 report, 1 independent Updated Aug 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

A price target raise for Hinge Health following the company's Q2 results and guidance, driven by the company's performance.

Who's involved

What this event is mainly about
Hinge Health

How it developed

Newest first. Tap a step to see who reported it.
  1. Daniel Perez was appointed Co-Founder and CEO of Hinge Health on August 6, 2025.Sub-event
  2. Truist raised its price target for Hinge Health following the company's Q2 results.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • TipRanksHinge Health price target raised to $62 from $48 at Truist Truist raised the firm’s price target on Hinge Health (HNGE) to $62 from $48 and keeps a Buy rating on the shares, updating the firm’s model